Demand for GLP-1 medications for weight loss is rising rapidly in Europe, especially in the United Kingdom, Germany and France
In the UK, researchers have estimated that approximately 1.6 million adults used weight-loss medications such as Wegovy and Mounjaro during 2024/2025, showing significant demand
In France, from June 2026, the country will be the first in Europe to begin covering the costs of weight-loss medication through the public <a href="https://healthylife7.com/us-healthcare-watchdog-claims-billions-in-expected-savings-as-enforcement-drops/” title=”US healthcare watchdog claims billions in expected savings as enforcement drops”>healthcare system, which is expected to make the medicine more accessible to citizens
Globally, the market is expected to more than double to $190bn in 2035, driven by increased adoption in the United States, Europe and other regions. This is a US news platform covering the healthcare sector, including pharmaceutical trends, policy and innovation
The development shows that obesity medication is becoming a global phenomenon … and that discussions about long-term health are relevant throughout the global community, reports Gustav H. Gram(pictured), CEO of Pila Pharma.
Not yet a Subscriber?
This is a small extract of the full article which is available
ONLY to premium content subscribers.
Click below to get premium content on Manufacturing Chemist
